Ligand Pharmaceuticals Inc
NASDAQ:LGND

  • LAST PRICE
    121.2500
  • TODAY'S CHANGE (%)
    -8.6500 (-6.6590%)
  • Bid / Lots
    121.0000/ 2
  • Ask / Lots
    127.9200/ 1
  • Open / Previous Close
    126.2700 / 129.9000
  • Day Range
    116.9600
    127.2600
  • 52 Week Range
    51.2100
    129.9000
  • Volume
    260,623

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
LGND
Ligand Pharmaceuticals Inc
2.4B
54.5x
-12.71%
HROW
Harrow Inc
1.8B
-55.2x
---
OCUL
Ocular Therapeutix Inc
1.7B
-10.2x
---
IMCR
Immunocore Holdings PLC
1.7B
-32.4x
---
AVDL
Avadel Pharmaceuticals PLC
1.5B
-13.6x
---
PHAT
Phathom Pharmaceuticals Inc
1.2B
-3.3x
---
As of 2024-11-09

Company Information

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Contact Information

Headquarters
3911 Sorrento Valley Blvd, Suite 110SAN DIEGO, CA, United States 92121
Phone
858-550-7500
Fax
302-636-5454

Executives

Independent Chairman of the Board
John Kozarich
Chief Executive Officer, Director
Todd Davis
Chief Financial Officer
Octavio Espinoza
Chief Legal Officer
Andrew Reardon
Independent Director
Jason Aryeh

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.4B
Revenue (TTM)
$133.5M
Shares Outstanding
18.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.07
EPS
$2.22
Book Value
$39.92
P/E Ratio
54.5x
Price/Sales (TTM)
17.8
Price/Cash Flow (TTM)
30.7x
Operating Margin
-14.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.